A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Once Weekly for 4 Weeks to Patients With Advanced Solid Tumors
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Itacnosertib (Primary)
- Indications Colorectal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America; Tolero Pharmaceuticals
- 13 Apr 2022 Preliminary Results (At data cutoff May 27, 2021) presented at the 113th Annual Meeting of the American Association for Cancer Research
- 08 Apr 2022 According to a Sumitomo Dainippon Pharma media release, data from this study will be presented at the American Association for Cancer Research (AACR) Annual Meeting
- 21 Oct 2021 Status changed from active, no longer recruiting to completed.